Soleno Therapeutics, Inc. (SLNO) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
SLNO Revenue Analysis (2014–2025)
As of March 2, 2026, Soleno Therapeutics, Inc. (SLNO) generated trailing twelve-month (TTM) revenue of $190.4 million. The most recent quarter (Q4 2025) recorded $91.7 million in revenue, up 38.9% sequentially.
Looking at the longer-term picture, SLNO's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $190.4 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including AGIO (+36.3% YoY), VRTX (+10.4% YoY), and ASND (+97.4% YoY). Compare SLNO vs AGIO →
Peer Comparison
Compare SLNO's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SLNOCurrent | $190M | - | - | 32.4% | |
| AGIO | $54M | +36.3% | - | -873.9% | |
| VRTX | $12.0B | +10.4% | +14.1% | 39.1% | |
| ASND | $692M | +97.4% | +150.9% | -18.9% | |
| BBIO | $502M | +126.3% | +127.4% | -113.3% | |
| BMRN | $3.2B | +12.9% | - | 16.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $190.4M | - | $0 | - | $61.7M | 32.4% |
| 2024 | $0 | - | $0 | - | $-187,671,000 | - |
| 2023 | $0 | - | $0 | - | $-41,384,000 | - |
| 2022 | $0 | - | $0 | - | $-24,397,000 | - |
| 2021 | $0 | - | $0 | - | $-31,528,000 | - |
| 2020 | $0 | - | $-2,194,000 | - | $-31,949,000 | - |
| 2019 | $0 | - | $-2,297,000 | - | $-23,197,000 | - |
| 2018 | $0 | +100.0% | $-1,919,000 | - | $-14,301,000 | - |
| 2017 | $-1,553,002,000 | -107145.4% | $-1,554,613,000 | 100.1% | $-12,171,315 | 0.8% |
| 2016 | $1.5M | +274.3% | $-58,518 | -4.0% | $-13,610,115 | -938.1% |
See SLNO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SLNO Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare SLNO vs AGIO
See how SLNO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is SLNO's revenue growth accelerating or slowing?
SLNO TTM revenue: $190M. YoY growth: N/A. 5-year CAGR: N/A.
What is SLNO's long-term revenue growth rate?
Soleno Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is SLNO's revenue distributed by segment?
SLNO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.